NCT01799538View on ClinicalTrials.gov

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 10, 2013

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2027

Conditions
Lymphangioleiomyomatosis
Interventions
DRUG

albuterol inhaler

2 puffs of Metered Dose inhaler for Bronchodilation

DRUG

albuterol nebulizer

Albuterol administered by nebulization will produce a greater increase in FEV1

PROCEDURE

PFT

Breathing Test

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH